Explains the alarming temporary increase in hair shedding that hits 2-8 weeks after starting topical or oral minoxidil — the most common reason users abandon the drug before it has time to work. Minoxidil is a K⁺-ATP channel opener; in vascular smooth muscle this drives the original-indication antihypertensive effect, but in the hair follicle the pharmacology is different (Suchonwanit 2019 review; Messenger 2004 mechanism summary). The active metabolite is minoxidil sulfate, formed in the follicle by SULT1A1 — sulfotransferase activity is the rate-limiting step and is the basis of the 20-40% non-responder phenotype (Goren 2014 / Roberts 2014 showed plucked-hair SULT1A1 activity predicts clinical response). Follicular K⁺-ATP opening and downstream effects (VEGF upregulation, PGE2 increase, β-catenin signaling in the dermal papilla, Buhl 1989) shorten the telogen (resting) phase and trigger premature anagen (growth) entry. The catch: telogen hairs about to fall out anyway are pushed out simultaneously to make room for the synchronized new anagen growth — producing the visible shed at weeks 2-8. The hairs released ARE the old, miniaturized ones that were going to shed eventually; their loss is necessary for replacement. New anagen hairs become visible around weeks 12-16, with full effect at 6-12 months. Counseling matters: users not warned about the shed often interpret it as drug failure and stop — Mysore counseling protocols and ISHRS guidelines now flag this as a key pre-prescription discussion item. Olsen 1986 was the first dose-response demonstration of clinical efficacy in male pattern baldness.
Organ Systems
integumentary
Pathway Steps
minoxidil → SULT1A1 conversion to minoxidil sulfate (in follicle) — via outer root sheath SULT1A1 converts minoxidil → minoxidil sulfate (active); 20-30× inter-individual activity variance. Minoxidil is a prodrug: the follicular enzyme sulfotransferase SULT1A1 converts it to the active minoxidil sulfate. Because individuals vary widely in follicular SULT1A1 activity, this conversion predicts who responds — and a SULT1A1 assay can forecast topical-minoxidil efficacy.
SULT1A1 conversion to minoxidil sulfate (in follicle) → K+ATP channel opening + dermal papilla VEGF / PGE2 / β-catenin signaling — via minoxidil sulfate opens K-ATP → hyperpolarization → ↑VEGF, PGE2 release, dermal papilla β-catenin (Messenger 2004). Minoxidil sulfate opens ATP-sensitive potassium (KATP) channels and stimulates dermal-papilla signaling (VEGF, PGE2, Wnt/β-catenin). These combined vascular and growth-factor effects prolong anagen and enlarge miniaturized follicles — the pro-growth actions underlying its benefit in AGA.
K+ATP channel opening + dermal papilla VEGF / PGE2 / β-catenin signaling → shortened telogen phase + premature anagen entry across follicles — via follicle cycle re-synchronization — many follicles pushed late-telogen → anagen simultaneously (Buhl 1989). By driving resting (telogen) follicles prematurely into the growth (anagen) phase, minoxidil synchronizes a cohort of follicles into a new cycle. This forced telogen-to-anagen transition is the key to its effect — but also sets up the transient shedding that precedes regrowth.
shortened telogen phase + premature anagen entry across follicles → visible shed at weeks 2-8 (old telogen hairs displaced by new anagen) — via the falling hairs are the old miniaturized telogen hairs being displaced by new anagen; reversible but alarming. As old telogen (club) hairs are pushed out by new anagen hairs emerging beneath them, users see a temporary increase in shedding around weeks 2-8 — the well-known “dread shed”. Counterintuitively this signals the drug is working, and it is self-limiting; warning patients prevents premature discontinuation.
visible shed at weeks 2-8 (old telogen hairs displaced by new anagen) → new anagen hair growth visible at weeks 12-16, full effect 6-12 months — via dose-response in Olsen 1986 (topical, MPB); oral 0.25-5 mg shows similar phenomenology; shed is a positive sign. New anagen hair becomes visible around weeks 12-16, with full effect by 6-12 months — the slow timeline set by hair-cycle biology. This is why minoxidil must be judged at months, not weeks, and why benefits reverse within months of stopping as follicles revert to their prior cycling.
Known Modulators
minoxidil (activator) — follicular K+ATP channel (via SULT1A1-activated minoxidil sulfate). topical 2-5% solution/foam BID was the original; oral low-dose (0.25-5 mg/day) is now widely used off-label with similar efficacy and shed-phase phenomenology — typically faster onset and more reliable absorption. Non-responders (~20-30%) have low follicular SULT1A1 activity — predictable with the Goren plucked-hair assay. Pre-treatment counseling about the shed is essential to retention